This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Play TheStreet's FDA Drug Approval Contest

BOSTON ( TheStreet) -- Back by popular demand, TheStreet's FDA Drug Approval Contest for 2013 -- with a few twists.

Your challenge: Correctly guess the outcome of the 12 regulatory events listed below. As a kicker to the contest, you're required to predict the outcome of a closely followed European drug approval decision, three FDA advisory panels and an accelerated approval meeting between a certain drug company and FDA officials.

Don't forget to answer the bonus question, as well.

To participate in the drug approval contest, please post your predictions to each of the 13 questions in the comments section under this story. Post your picks by Friday, March 8 at 4 pm ET. Entries posted after the deadline will not count, so don't be tardy with your picks. Enter now!

As with my previous drug-approval contests, winners will be lauded for their intelligence on Twitter and in future columns. Losers will be mocked gently.

Good luck!

1. Sarepta Therapeutics (SRPT - Get Report): The FDA will grant the company's request to seek accelerated approval for eteplirsen. Yes or No?

2. Arena Pharmaceuticals (ARNA - Get Report): The European Medicine Agency's CHMP will recommend approval of the weight-loss drug Belviq. Yes or No?

3. Titan Pharmaceuticals (TTNP - Get Report): FDA advisory panel for Probuphine on March 21. Positive or negative vote?

4. A.P. Pharma (APPA): FDA approval decision for APF530 on March 27: Approve or Reject?

5. Biogen Idec (BIIB): FDA approval decision for BG-12 on March 28. Approve or Reject?

6. United Therapeutics (UTHR): FDA approval decision for oral Remodulin on March 29. Approve or Reject?

7. Sucampo Pharmaceuticals (SCMP): FDA approval decision for Amitiza on April 26. Approve or Reject?

8. Navidea Biopharmaceutials (NAVB): FDA approval decision for Lymphoseek on April 30. Approve or Reject?

9. Raptor Pharmaceuticals (RPTP): FDA approval decision for Procysbi on April 30. Approve or Reject?

10. Aveo Pharmaceuticals (AVEO): FDA advisory panel for Tivopath on May 2. Positive or negative vote?

11. Delcath Systems (DCTH - Get Report): FDA advisory panel for ChemoSat (now known as Melblez) on May 2. Positive or negative vote?

12. Delcath Systems: FDA approval decision for Melblez on June 14. Approve or Reject?

13. Bonus question: Will the Ziopharm (ZIOP - Get Report) phase III study of palifosfamide in sarcoma be successful (defined as meeting the PFS primary endpoint with statistical significance.) Yes or No?

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ZIOP $7.86 0.00%
ARNA $1.72 0.00%
DCTH $0.32 0.00%
SRPT $14.19 0.00%
TTNP $5.95 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs